Literature DB >> 24592041

Management of retained products of conception with marked vascularity.

Veena Aseeja1.   

Abstract

To discuss the management options of retained products of conception (RPOC) with increased vascularity where simple dilatation and curettage may lead to life threatening haemorrhage and endanger the life of the patient. We present a series of three cases that had RPOC with hyper vascularity and were managed with different approaches. A brief review of management options is discussed. Out of three cases of RPOC with hyper vascularity, two cases underwent hysterectomy and one case was managed with methotrexate. From our study and review of literature, we conclude that evaluation of vascularity in all cases of RPOC is mandatory prior to Dilatation&Curettage in order to avoid the dreaded complication of massive haemorrhage.

Entities:  

Keywords:  Doppler study; Retained products of conception; increased vascularity; management options

Year:  2012        PMID: 24592041      PMCID: PMC3939244          DOI: 10.5152/jtgga.2012.31

Source DB:  PubMed          Journal:  J Turk Ger Gynecol Assoc        ISSN: 1309-0380


  4 in total

1.  Management of retained products of conception with marked vascularity.

Authors:  Tomoko Kitahara; Yukiyasu Sato; Kazuyo Kakui; Keiji Tatsumi; Hiroshi Fujiwara; Ikuo Konishi
Journal:  J Obstet Gynaecol Res       Date:  2011-01-05       Impact factor: 1.730

2.  Abnormal placentation: twenty-year analysis.

Authors:  Serena Wu; Masha Kocherginsky; Judith U Hibbard
Journal:  Am J Obstet Gynecol       Date:  2005-05       Impact factor: 8.661

3.  Placenta accreta/increta. Review of 10 cases and a case report.

Authors:  Y Ota; H Watanabe; I Fukasawa; S Tanaka; T Kawatsu; A Oishi; S Yasuda; N Inaba
Journal:  Arch Gynecol Obstet       Date:  1999-11       Impact factor: 2.344

4.  Retained products of conception: spectrum of color Doppler findings.

Authors:  Aya Kamaya; Ivan Petrovitch; Bertha Chen; Carrie E Frederick; R Brooke Jeffrey
Journal:  J Ultrasound Med       Date:  2009-08       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.